Nektar Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Nektar Therapeutics'in kazancının yıllık 6.1% oranında azalması, yıllık gelirinin ise yıllık 11.8% oranında artması beklenmektedir. EPS'nin yılda 7.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -191.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

-6.1%

Kazanç büyüme oranı

7.1%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.7%
Gelir büyüme oranı	11.8%
Gelecekteki özkaynak getirisi	-191.8%
Analist kapsamı	Good
Son güncelleme	19 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Oct 18

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:NKTR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	83	-193	-198	-153	7
12/31/2025	84	-174	-170	-142	7
12/31/2024	100	-154	-111	-132	7
9/30/2024	93	-168	-178	-177	N/A
6/30/2024	93	-177	-175	-175	N/A
3/31/2024	90	-176	-189	-189	N/A
12/31/2023	90	-276	-193	-193	N/A
9/30/2023	88	-294	-204	-203	N/A
6/30/2023	88	-307	-245	-244	N/A
3/31/2023	89	-415	-269	-267	N/A
12/31/2022	92	-368	-310	-304	N/A
9/30/2022	95	-454	-409	-398	N/A
6/30/2022	96	-525	-430	-416	N/A
3/31/2022	103	-491	-440	-424	N/A
12/31/2021	102	-524	-428	-413	N/A
9/30/2021	100	-495	-371	-360	N/A
6/30/2021	105	-474	-321	-311	N/A
3/31/2021	126	-429	-322	-312	N/A
12/31/2020	153	-444	-321	-313	N/A
9/30/2020	163	-439	-349	-340	N/A
6/30/2020	163	-429	-368	-356	N/A
3/31/2020	137	-460	-347	-326	N/A
12/31/2019	115	-441	-355	-329	N/A
9/30/2019	121	-427	-352	-321	N/A
6/30/2019	119	-424	-352	-324	N/A
3/31/2019	1,184	657	671	690	N/A
12/31/2018	1,193	681	704	718	N/A
9/30/2018	1,249	746	747	755	N/A
6/30/2018	1,374	903	N/A	920	N/A
3/31/2018	321	-129	N/A	-98	N/A
12/31/2017	308	-97	N/A	-80	N/A
9/30/2017	250	-105	N/A	-52	N/A
6/30/2017	133	-209	N/A	-173	N/A
3/31/2017	131	-198	N/A	-128	N/A
12/31/2016	165	-154	N/A	-117	N/A
9/30/2016	167	-165	N/A	-140	N/A
6/30/2016	191	-130	N/A	-126	N/A
3/31/2016	181	-134	N/A	-160	N/A
12/31/2015	231	-81	N/A	-73	N/A
9/30/2015	211	-73	N/A	-23	N/A
6/30/2015	284	6	N/A	-55	N/A
3/31/2015	290	26	N/A	-16	N/A
12/31/2014	201	-54	N/A	-142	N/A
9/30/2014	212	-56	N/A	-64	N/A
6/30/2014	140	-143	N/A	-37	N/A
3/31/2014	146	-153	N/A	-63	N/A
12/31/2013	149	-162	N/A	-39	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: NKTR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: NKTR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: NKTR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: NKTR şirketinin gelirinin (yıllık 11.8% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: NKTR şirketinin gelirinin (yıllık 11.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: NKTR 3 yıl içinde kârsız olması bekleniyor.

Nektar Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 22%

Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024

Consensus EPS estimates fall by 12%

Price target decreased by 83% to US$0.50

Price target increased by 21% to US$2.88

Price target increased by 14% to US$2.70

Recent updates

Consensus revenue estimates increase by 22%

Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million.

Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million.

New major risk - Revenue and earnings growth

Nektar Therapeutics to Report Q3, 2024 Results on Nov 07, 2024

Nektar Therapeutics Announces Publication in Nature Communications of Results from Phase 1B Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Nektar Therapeutics Announces Publication in Blood of Phase 1 Data for Novel II-15 Agonist NKTR-255 in Combination with Autologous CD19-22 Car-T Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Nektar Therapeutics to Report Q2, 2024 Results on Aug 08, 2024

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Nektar Therapeutics to Report Q1, 2024 Results on May 09, 2024

Nektar Therapeutics, Annual General Meeting, Jun 05, 2024

New major risk - Share price stability

Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC

Consensus EPS estimates fall by 12%

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC

Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Price target decreased by 83% to US$0.50

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023

Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer

Price target increased by 21% to US$2.88

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis

Price target increased by 14% to US$2.70

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023

Price target decreased by 7.3% to US$2.35

New minor risk - Market cap size

Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index

New minor risk - Market cap size

Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule

Price target increased by 18% to US$3.00

Consensus EPS estimates fall by 63%, revenue upgraded

Price target decreased by 7.8% to US$2.70

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 21% to US$3.60

CEO, President & Director recently sold US$59k worth of stock

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Insufficient new directors

CEO, President & Director recently sold US$136k worth of stock

Insider recently sold US$48k worth of stock

Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

Independent Director notifies of intention to sell stock

Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress

Insider notifies of intention to sell stock

CEO, President & Director recently sold US$65k worth of stock

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma